SCNI
Scinai Immunotherapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.86
−4.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5M | 1.3M | 658.0K | — | — |
| Cost of Revenue | 5.3M | 4.0M | 1.2M | — | — |
| Gross Profit | (3.8M) | (2.7M) | (580.0K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 2.0M | 2.4M | 5.5M | 5.2M | 5.8M |
| SG&A Expense | 2.7M | 2.5M | 2.5M | 4.5M | 5.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | (9.0K) | — |
| Total Operating Expenses | 4.7M | 4.9M | 8.1M | 9.7M | 11.1M |
| Cost and Expenses | 9.9M | 8.9M | 9.3M | 9.7M | 11.1M |
| Operating Income (EBIT) | (8.4M) | (7.5M) | (8.6M) | (9.7M) | (11.1M) |
| Non-Operating | |||||
| Interest Income | 32.0K | 20.0K | 100.5K | 3.9M | 3.1M |
| Interest Expense | 215.4K | 359.0K | 1.4M | 3.8M | — |
| Net Interest Income | (183.4K) | (339.0K) | (1.3M) | 123.0K | 3.1M |
| Other Non-Op Income/Expense | 5.8M | (765.0K) | 13.4M | 3.2M | 5.3M |
| Non-Operating Income (excl Interest) | — | 406.0K | — | (7.0M) | (5.3M) |
| EBT (Pre-Tax Income) | (2.6M) | (8.3M) | 4.8M | (6.5M) | (5.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (2.6M) | (8.3M) | 4.8M | (6.5M) | (5.8M) |
| Earnings from Cont. Ops | (2.6M) | (8.3M) | 4.8M | (6.5M) | (5.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.6M) | (8.4M) | 4.8M | (6.5M) | (5.8M) |
| Per Share | |||||
| Basic EPS | ($62,161.60) | ($36.00) | $60.00 | ($64,000.00) | ($160,000.00) |
| Diluted EPS | ($62,161.60) | ($36.00) | $60.00 | ($64,000.00) | ($160,000.00) |
| Revenue Per Share | $0.03 | $5.61 | $8.16 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 57.0M | 233486 | 80636 | 97 | 47 |
| Diluted Shares Outstanding | 57.0M | 233486 | 80636 | 97 | 47 |
| Profitability Metrics | |||||
| EBITDA | (6.7M) | (6.5M) | (7.0M) | (2.2M) | (5.2M) |
| D&A | 1.8M | 1.4M | 1.6M | 514.0K | 562.0K |
| EBIT | (8.4M) | (7.9M) | (8.6M) | (2.7M) | (5.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026